Novozymes, Inc. 9M Sales And Profit In Line With August Expectations; Full-Year Outlook Narrowed
Novozymes 9M sales and profit in line with August expectations; full-year outlook narrowed
COPENHAGEN, Denmark – October 22, 2015 – Novozymes, the world’s largest producer of industrial enzymes, today announced its results for the first nine months 2015. Sales grew by 4% organically and by 14% in DKK compared with 9M 2014. EBIT grew by 15%, and the EBIT margin was 27.7%. Net profit grew by 11%, and free cash flow before acquisitions came in at DKK 2,022 million. In Q3 alone, sales grew by 3% organically and by 11% in DKK compared with Q3 2014.
The 2015 outlook for organic sales growth is adjusted within the previous range to 4-5% (4-7% at previous guidance). Sales in DKK are now expected to increase by 12-13% (13-16% at previous guidance). The expectation for EBIT growth is adjusted to ~15% and net profit growth to ~12% (15-17% and 11-13% respectively at previous guidance). The expectation for EBIT margin is unchanged.
Peder Holk Nielsen, President and CEO of Novozymes, comments:
“Our performance was in line with expectations nine months into the year: record earnings on a relatively low topline growth. We're on track to meet the full-year organic sales and profit outlook, as we continue to focus our efforts on driving innovation and sales growth.”
Novozymes Q3 results
Novozymes’ executive leadership team will present the results at a conference call today at 12:00 pm CET:
http://www.novozymes.com/en/investor/events-presentations/Pages/conference-call.aspx
The entire earnings report can be downloaded at news.novozymes.com.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com
NASDAQ OMX: NZYM-B • 6,500 employees • DKK 12 billion turnover • 30+ industries • 700+ products
Media contacts
Europe
Frederik Bjørndal
Phone: +44 7976138265
tfbh@novozymes.com
Denmark
René Tronborg
Phone: +45 30772274
retr@novozymes.com
Investor contacts
Europe
Thomas Steenbech Bomhoff
Phone: +45 3077 1226
tsbm@novozymes.com
US
Martin Riise
Phone: +1 919 649 2565
mrsn@novozymes.com
Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark
Help employers find you! Check out all the jobs and post your resume.
COPENHAGEN, Denmark – October 22, 2015 – Novozymes, the world’s largest producer of industrial enzymes, today announced its results for the first nine months 2015. Sales grew by 4% organically and by 14% in DKK compared with 9M 2014. EBIT grew by 15%, and the EBIT margin was 27.7%. Net profit grew by 11%, and free cash flow before acquisitions came in at DKK 2,022 million. In Q3 alone, sales grew by 3% organically and by 11% in DKK compared with Q3 2014.
The 2015 outlook for organic sales growth is adjusted within the previous range to 4-5% (4-7% at previous guidance). Sales in DKK are now expected to increase by 12-13% (13-16% at previous guidance). The expectation for EBIT growth is adjusted to ~15% and net profit growth to ~12% (15-17% and 11-13% respectively at previous guidance). The expectation for EBIT margin is unchanged.
Peder Holk Nielsen, President and CEO of Novozymes, comments:
“Our performance was in line with expectations nine months into the year: record earnings on a relatively low topline growth. We're on track to meet the full-year organic sales and profit outlook, as we continue to focus our efforts on driving innovation and sales growth.”
Novozymes Q3 results
Novozymes’ executive leadership team will present the results at a conference call today at 12:00 pm CET:
http://www.novozymes.com/en/investor/events-presentations/Pages/conference-call.aspx
The entire earnings report can be downloaded at news.novozymes.com.
About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com
NASDAQ OMX: NZYM-B • 6,500 employees • DKK 12 billion turnover • 30+ industries • 700+ products
Media contacts
Europe
Frederik Bjørndal
Phone: +44 7976138265
tfbh@novozymes.com
Denmark
René Tronborg
Phone: +45 30772274
retr@novozymes.com
Investor contacts
Europe
Thomas Steenbech Bomhoff
Phone: +45 3077 1226
tsbm@novozymes.com
US
Martin Riise
Phone: +1 919 649 2565
mrsn@novozymes.com
Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark
Help employers find you! Check out all the jobs and post your resume.